Evidence map›Paper›PMID 41599406›Full record

ReviewMolecules (Basel, Switzerland)2026

Suzetrigine, a Na

Rawan M Medhat, Omnia A Kotb, Daniel Baecker

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rawan M MedhatDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria 21648, Egypt.ORCID 0000-0002-0818-7469
Omnia A KotbDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria 21648, Egypt.ORCID 0009-0007-8981-4973
Daniel BaeckerDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195 Berlin, Germany.ORCID 0000-0002-1963-9838

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suzetrigine was approved by the US American Food and Drug Administration in 2025 as the first oral, non-opioid, selective inhibitor of Na

Indexed as

AnalgesicsNAV1.8 Voltage-Gated Sodium ChannelPainSodium Channel BlockersAmidesAminopyridinesAnimalsFuransHumansAmidesAminopyridinesAnalgesicsFuransNAV1.8 Voltage-Gated Sodium ChannelSodium Channel Blockerssuzetrigineacute painNaV1.8non-opioid analgesicsodium channelsuzetrigine

Identifiers

PMID41599406
PMCPMC12843740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.